8-K: Eli Lilly Completes Acquisition of Verve Therapeutics for $10.50 Cash Plus CVR
Sentiment:
Merger Completion
Eli Lilly and Company has successfully completed its tender offer and subsequent merger to acquire Verve Therapeutics, Inc., making Verve a wholly-owned subsidiary.
Summary
- Eli Lilly and Company, through its indirect wholly-owned subsidiary Ridgeway Acquisition Corporation, has completed the acquisition of Verve Therapeutics, Inc.
- The tender offer for Verve's common stock expired on July 23, 2025, at 11:59 p.m. Eastern Time, and was not extended.
- Approximately 49,882,464 shares, representing 55.7% of the issued and outstanding shares, were validly tendered and not withdrawn, satisfying the minimum tender condition.
- On July 24, 2025, Eli Lilly and Ridgeway Acquisition Corporation accepted for payment all validly tendered shares.
- The offer price was $10.50 per share in cash, plus one non-tradable contingent value right (CVR) per share, which represents the contractual right to receive up to $3.00 per CVR upon the achievement of a specified milestone.
- On July 25, 2025, Ridgeway Acquisition Corporation merged with and into Verve Therapeutics, Inc., with Verve continuing as the surviving corporation and becoming an indirect wholly-owned subsidiary of Eli Lilly.
- Verve's common stock trading on Nasdaq Global Select Market was suspended effective as of the close of business on July 24, 2025, and the company will be delisted and deregistered from the SEC.
- Outstanding Company Stock Options with an exercise price less than the Cash Consideration were cancelled and converted into cash and one CVR per share.
- Company Stock Options with an exercise price equal to or greater than the Cash Consideration and less than the sum of the Cash Consideration and the Milestone Payment were cancelled and converted into a cash payment based on the CVR value.
- Company Stock Options with an exercise price equal to or greater than the sum of the Cash Consideration and the Milestone Payment were cancelled for no consideration.
- Outstanding and unvested Restricted Stock Units (RSUs) became immediately vested in full and were cancelled, converting into cash and one CVR per share.
- Several material definitive agreements and equity incentive plans, including the Investors Rights Agreement and the Open Market Sale Agreement with Jefferies LLC, were terminated effective as of the merger's effective time.
Sentiment
Score: 7
Explanation: The filing reports the successful and expected completion of an acquisition, providing a cash premium and a contingent value right to shareholders, which is generally a positive outcome for the acquired company's investors.
Positives
- Verve Therapeutics shareholders received a cash consideration of $10.50 per share, representing a premium over the pre-announcement trading price.
- Shareholders also received a contingent value right (CVR) potentially worth up to an additional $3.00 per share, offering upside based on future milestone achievement.
- The successful completion of the tender offer and merger provides liquidity and a defined exit for Verve's public shareholders.
Negatives
- Verve Therapeutics, Inc. ceased to be an independent publicly traded company, with its common stock delisted from Nasdaq.
- The contingent value right (CVR) is non-tradable, limiting liquidity for this portion of the consideration.
- A portion of the equity awards (options with high exercise prices) were cancelled for no consideration.
Risks
- The contingent payment of up to $3.00 per CVR is subject to the achievement of a certain specified milestone, meaning the full $3.00 is not guaranteed.
- Shareholders who did not tender their shares or properly exercise appraisal rights will receive the same Offer Price, but the company will no longer be publicly traded, limiting future liquidity for those shares.
Future Outlook
Verve Therapeutics, Inc. is now an indirect wholly-owned subsidiary of Eli Lilly and Company, and its future operations and strategic direction will be integrated into Eli Lilly's broader corporate strategy. The contingent value right (CVR) offers a potential future payment to former shareholders upon the achievement of a specific milestone.
Industry Context
This acquisition represents a common strategic move in the biotechnology and pharmaceutical industry, where larger companies like Eli Lilly acquire smaller, innovative firms to expand their pipeline, gain access to new technologies (such as gene editing), and enhance their market position. Such mergers often provide a clear exit strategy and liquidity for the acquired company's shareholders.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Director | Sekar Kathiresan | 2025-07-25 | Resigned in connection with the merger. | |
| Director | Burt Adelman | 2025-07-25 | Resigned in connection with the merger. | |
| Director | Lonnel Coats | 2025-07-25 | Resigned in connection with the merger. | |
| Director | Alexander Cumbo | 2025-07-25 | Resigned in connection with the merger. | |
| Director | Michael MacLean | 2025-07-25 | Resigned in connection with the merger. | |
| Director | Sheila Mikhail | 2025-07-25 | Resigned in connection with the merger. | |
| Director | Jodie Morrison | 2025-07-25 | Resigned in connection with the merger. | |
| Director | Ourania Tatsis | 2025-07-25 | Resigned in connection with the merger. | |
| Director | Krishna Yeshwant | 2025-07-25 | Resigned in connection with the merger. | |
| Director | Christopher Anderson | 2025-07-25 | Appointed in connection with the merger. | |
| Director | Jonathan R. Haug | 2025-07-25 | Appointed in connection with the merger. | |
| Director | Sherry D. Davis | 2025-07-25 | Appointed in connection with the merger. | |
| Officer | All incumbent officers | 2025-07-25 | Removed immediately following completion of the merger. | |
| President | Jonathan R. Haug | 2025-07-25 | Appointed in connection with the merger. | |
| Secretary | Christopher Anderson | 2025-07-25 | Appointed in connection with the merger. | |
| Treasurer | Steffanie Lim-Ho | 2025-07-25 | Appointed in connection with the merger. | |
| Assistant Treasurer | Katie Lodato | 2025-07-25 | Appointed in connection with the merger. | |
| Assistant Secretary | Jonathan Groff | 2025-07-25 | Appointed in connection with the merger. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Certificate of Incorporation Amendment | The certificate of incorporation was amended and restated in its entirety to the Fifth Amended and Restated Certificate of Incorporation. This includes changes to authorized shares (now 100 common shares, $0.0001 par value), exclusive voting rights for common stock, director removal provisions (with or without cause by majority vote), board's power to amend bylaws, and detailed indemnification provisions for directors and officers. | 2025-07-25 | Significantly alters the corporate structure and governance framework, aligning it with the new status as a wholly-owned subsidiary of Eli Lilly. The reduction in authorized shares and changes to voting rights reflect the company's transition from a public entity to a private one. |
| Bylaws Amendment | The bylaws were amended and restated in their entirety to the Third Amended and Restated Bylaws. This includes provisions for annual and special meetings, stockholder lists, quorum requirements, voting procedures, board of directors' powers (including fixing director compensation and filling vacancies), committee appointments, and officer elections and duties. | 2025-07-25 | Updates the internal operating rules to reflect the company's new ownership and governance structure, streamlining decision-making processes under the parent company's control. |
| Agreement Termination | The Second Amended and Restated Investors Rights Agreement, dated January 14, 2021, was terminated. | 2025-07-25 | Eliminates previous investor rights and obligations, consistent with the company's transition to a wholly-owned subsidiary. |
| Plan Termination | The Amended and Restated 2021 Employee Stock Purchase Plan, the Endcadia, Inc. 2018 Equity Incentive Plan, the Verve Therapeutics, Inc. 2021 Stock Incentive Plan, and the Verve Therapeutics, Inc. 2024 Inducement Stock Incentive Plan were terminated. | 2025-07-25 | Ceases all previous equity incentive programs, as employee compensation and benefits will now fall under Eli Lilly's policies. |
| Agreement Termination | The Open Market Sale Agreement, dated July 1, 2022, with Jefferies LLC was terminated. | 2025-07-25 | Ends the company's ability to sell shares on the open market, consistent with its delisting and private status. |
Related Party Transactions
- The entire acquisition of Verve Therapeutics, Inc. by Eli Lilly and Company, through its indirect wholly-owned subsidiary Ridgeway Acquisition Corporation, constitutes a significant related party transaction, as Verve becomes a subsidiary of Eli Lilly.
Stakeholder Impact
- Shareholders: Received $10.50 per share in cash and one non-tradable CVR per share, providing a premium and potential future upside, but losing their investment in a publicly traded entity.
- Employees: The management team has been replaced, and existing equity incentive plans have been terminated, indicating a shift in corporate culture and compensation structures under Eli Lilly's ownership.
- Customers/Suppliers: No direct impact mentioned, but operations will now be integrated into Eli Lilly's larger framework, potentially affecting existing relationships.
- Creditors: The acquisition was funded by Eli Lilly's cash and borrowings, suggesting a stable financial backing for Verve's ongoing operations.
Next Steps
- Nasdaq will file a Form 25, Notification of Removal from Listing and/or Registration, to delist all Verve Common Stock from Nasdaq and deregister it under Section 12(b) of the Securities Exchange Act of 1934.
- Verve Therapeutics intends to file a Certification and Notice of Termination of Registration on Form 15 with the SEC to terminate registration of its common stock under Section 12(g) of the Exchange Act and suspend its reporting obligations under Sections 13 and 15(d) of the Exchange Act.
Key Dates
| Date | Description |
|---|---|
| 2021-01-14 | Date of the Second Amended and Restated Investors Rights Agreement, which was terminated. |
| 2022-07-01 | Date of the Open Market Sale Agreement with Jefferies LLC, which was terminated. |
| 2025-06-16 | Date of the Agreement and Plan of Merger. |
| 2025-06-17 | Date of the Current Report on Form 8-K filed by Verve Therapeutics, Inc. disclosing the Merger Agreement. |
| 2025-06-25 | Purchaser commenced the tender offer to purchase all outstanding shares of Verve Therapeutics. |
| 2025-07-23 | Tender offer and related withdrawal rights expired at one minute past 11:59 p.m., Eastern Time. This is also the earliest event reported date for the 8-K filing. |
| 2025-07-24 | Parent and Purchaser accepted for payment the shares validly tendered. Joint press release issued by Verve and Eli Lilly. Nasdaq suspended trading of Verve Common Stock effective as of close of business. |
| 2025-07-25 | Purchaser merged with and into Verve Therapeutics, Inc., making Verve an indirect wholly-owned subsidiary of Eli Lilly. This is also the filing date of the 8-K. |
Keywords
Verve Therapeutics, Eli Lilly, Acquisition, Merger, Tender Offer, Biotechnology, Pharmaceuticals, Gene Editing, CVR, Delisting, Corporate Governance
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.